Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REOLYSIN with Paclitaxel and Carboplatin in KRAS/EGFR-Activated NSCLC
NCT00861627Phase 2Completed
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Mar 2009
- Primary completion
- Sep 2015
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pelareorep in non-small cell lung cancer (NSCLC), sponsored by Oncolytics Biotech Inc. Primary endpoint: Objective Response Rate. Started Mar 2009; status: completed.
02
Drugs
pelareorep
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00861627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861627.